In 2022, the new drug Akoladine was recruited. Akoladine (IC- 162) is a single effective component extracted from Herba Epimedii, which can specifically bind to small molecular compounds of ER-α36 receptor, specifically activate ERK signaling pathway mediated by tumor stem cells expressing ER-α36, and promote cell apoptosis through JNK/SAPK pathway. At present, patients with liver cancer are recruited regularly, and 200 people are planned to be recruited, all of which must meet the selection criteria. (See the "Global Oncologist" platform for the selection criteria).